Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18113539 | STABILIZED PEPTIDE-MEDIATED TARGETED PROTEIN DEGRADATION | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 17614949 | METHODS OF TREATING HYPERLIPIDEMIA CONDITIONS WITH NETRIN-1 COMPOUNDS | Non-Final OA | The Regents of The University of California |
| 17441922 | SUMO PEPTIDES FOR TREATING NEURODEGENERATIVE DISEASES | Final Rejection | The Chinese University of Hong Kong |
| 17700055 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST | Non-Final OA | HANMI PHARM. CO., LTD |
| 18283164 | GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION, AND USE | Final Rejection | BrightGene Bio-Medical Technology Co., Ltd. |
| 18245991 | COMPOUND FOR INCREASING THE EFFICACY OF FACTOR VIII REPLACEMENT THERAPY | Non-Final OA | ABLEVIA BIOTECH GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy